TriangleCyclophosphamide (NCT03099356)
Cyclophosphamide trial for Metastatic Thyroid Cancer (NCT03099356). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with progressing differentiated thyroid cancer that cannot receive, or has declined, treatment intended to eliminate it. Radioactive iodine must have failed or be unsuitable; previous mTOR inhibitors exclude participation.
The idea: cyclophosphamide disrupts DNA copying, while sirolimus blocks mTOR signaling. Orally: sirolimus four milligrams on days one through twenty-eight, and cyclophosphamide 100 milligrams on days one through five and fifteen through nineteen. Imaging checks response every two cycles.
This phase 2 study plans 22 patients. Paul Swiecicki leads at Michigan in Ann Arbor, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.